| Hazard Information | Back Directory | [Uses]
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1]. | [in vivo]
Vanucizumab (20 mg/kg; i.p.; once weekly; for 6 weeks) shows tumor growth inhibition and induces tumor stasis[2]. | Animal Model: | SCID beige mice bearing Colo205 cells[2] | | Dosage: | 20 mg/kg | | Administration: | i.p.; once weekly; for 6 weeks | | Result: | Showed tumor growth inhibition.
|
| [References]
[1] Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. DOI:10.1158/1078-0432.CCR-17-1588
[2] Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. DOI:10.1073/pnas.1019002108 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|